DALLAS and NEW YORK, Feb. 6,
2015 /PRNewswire/ -- PlasmaTech Biopharmaceuticals,
Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein
biologic therapies and oncology supportive care products, announced
today that Scott Schorer, CEO, will
be presenting a corporate update at the 17th Annual
BIO CEO & Investor
Conference. The presentation will take place on Monday, February 9, 2015, at 5:00 pm ET in the Park South room at the Waldorf
Astoria Hotel in New York,
NY. Management from PTBI is available throughout the
conference for one-on-one meetings as well.
A copy of the presentation will be available on our corporate
website at www.plasmatechbio.com.
About PlasmaTech Biopharmaceuticals, Inc.:
PlasmaTech Biopharmaceuticals, Inc. (PlasmaTech) is a
biopharmaceutical company focused on advancing targeted treatments
for significant unmet needs of critical patient care.
Exploiting two distinct proprietary platforms, Salt Diafiltration
(SDF™) Process and Polymer Hydrogel Technology (PHT™), PlasmaTech
is active in the development and commercialization of
plasma-derived therapeutics and cancer supportive care products.
The Company has developed a robust product pipeline that includes
two commercial stage products, MuGard® and ProctiGard™ as well as
multiple pre-clinical follow-on products. For more information
visit, www.plasmatechbio.com.
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended, and that involve risks and uncertainties.
These statements include those relating to: timelines and clinical
results for MuGard and ProctiGard, our ability to achieve clinical
and commercial success and our ability to successfully develop
marketed products. These statements are subject to numerous risks,
including but not limited to PlasmaTech's need to obtain additional
financing in order to continue clinical trials and operations and
to the risks detailed in PlasmaTech's Annual Reports on Form 10-K
and other reports filed by the Company with the Securities and
Exchange Commission.
Company and Media Contact:
Harrison Wehner
President & CFO
PlasmaTech Biopharmaceuticals, Inc.
(617) 981-6955
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/plasmatech-biopharmaceuticals-to-present-at-17th-annual-bio-ceo--investor-conference-300032191.html
SOURCE PlasmaTech Biopharmaceuticals, Inc.